Publikace
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome2020 | Publikace bez příslušnosti k fakultě
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial2019 | Publikace bez příslušnosti k fakultě
- Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes2019 | Publikace bez příslušnosti k fakultě
- Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial2019 | Publikace bez příslušnosti k fakultě
- Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial2019 | Publikace bez příslušnosti k fakultě
- Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery2019 | Publikace bez příslušnosti k fakultě
- Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial2019 | Publikace bez příslušnosti k fakultě
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome2018 | Publikace bez příslušnosti k fakultě
- Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)2010 | 2. lékařská fakulta
- Pregnancy-associated plasma protein A and proform eosinophilic major basic protein in the detection of different types of coronary artery disease2008 | 2. lékařská fakulta, 1. lékařská fakulta, Fakulta tělesné výchovy a sportu, Ústřední knihovna
Loading network view...